ro13-9904 and Oophoritis

ro13-9904 has been researched along with Oophoritis* in 1 studies

Trials

1 trial(s) available for ro13-9904 and Oophoritis

ArticleYear
C-reactive protein and the treatment of pelvic inflammatory disease.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1998, Volume: 60, Issue:2

    The significance of C-reactive protein (CRP) in assessing the treatment of pelvic inflammatory disease (PID) was established and compared with body temperature (BT), erythrocyte sedimentation rate (ESR) and serum leukocyte concentration (L).. In 51 patients with PID, 20 (39%) of them with tubo-ovarial abscess (TOA), measurement of BT and laboratory investigations were carried out on admission and during treatment on days 3-4, 6-8 and 18-21. The changes in these values were compared with the changes in clinical condition.. Prior to treatment, the majority--49 patients or 96.1%--had increased CRP values. In successful treatment, the CRP values decreased significantly in PID patients without TOA on day 3-4, in patients with TOA on day 6-8 and reached normal values in both groups on day 18-21. Changes in clinical condition were most concurrent with changes in CRP.. In assessing PID treatment, the determination of CRP has precedence over L, ESR and BT as the percentage of patients with increased CRP is higher and because the changes in value follow the changes in clinical condition more reliably.

    Topics: Abscess; Adult; Blood Sedimentation; Body Temperature; C-Reactive Protein; Ceftriaxone; Clindamycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gentamicins; Humans; Oophoritis; Pelvic Inflammatory Disease; Prognosis; Prospective Studies; Salpingitis; Sensitivity and Specificity; Severity of Illness Index; Tetracycline

1998